Expanded Access Policy

Simcere Zaiming will present six innovative researches at the 2024 AACR

Simcere Zaiming announces global FIH dosing of USP1 inhibitor in clinical trial

Phase III Clinical Study of Daridorexant Achieved the Full Patient Enrollment in China

New Drug Application Of Suvemcitug For Injection Has Been Accepted By the China National Medical Products Administration

SIM0500, Simcere Zaiming’s Tri-specific Antibody Candidate for Multiple Myeloma Achieved Concurrent Approval for Clinical Trials in both the United States and China

SIM0501 Tablets, a USP1 Small-Molecule Inhibitor, Obtained Clinical Trial Approval in China

Stanford and Simcere Enter Parkinson's Research Collaboration

Suvemcitug met primary endpoint in Phase 3 Clinical Trial in China

LOCALIZATION APPLICATION OF COSELA^® (TRILACICLIB HYDROCHLORIDE FOR INJECTION) APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA